Washington, DC 20006-5349
HELPLINE
This MesoTV panel of four mesothelioma patients and one caregiver discuss survivors’ guilt and other issues affecting mesothelioma survivors. Chris
Today, the Mesothelioma Applied Research Foundation, among 130 organizations, cancer centers, and other institutions, sent a letter to President Joseph
As we thought about our 2020 year in review, we were, of course, reminded that this year was a time
A phase 2 immunotherapy clinical trial combining durvalumab, an immunotherapy drug, with standard treatment of Alimta (pemetrexed)/cisplatin has shown promising overall survival results. The
Despite initial positive signs from its phase 2 counterpart, the phase 3 LUME-Meso trial in malignant pleural mesothelioma did not
The short answer is: no. Maintenance pemetrexed (Alimta) following standard treatment of pemetrexed (Alimta)/cisplatin does not prolong progression-free survival in
The Mesothelioma Applied Research Foundation, Inc. (“MESO FOUNDATION”) values your trust, and we understand the importance of protecting your privacy.
The National Cancer Institute recently announced that it will be funding a five-year, $10.7 million grant for research into how
Last Friday, October 5, we made our second and final stop on the 2018 International Symposium on Malignant Mesothelioma tour
The Mesothelioma Applied Research Foundation is the only national 501(c)3 nonprofit organization that funds peer-reviewed research, provides education and patient services, and advocates for
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
